Akero Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Akero Therapeutics reports Q3 2025 results, highlighting progress in its Phase 3 SYNCHRONY program for MASH and the pending acquisition by Novo Nordisk for $54.00 cash plus a $6.00 CVR per share.
Akero Therapeutics reports increased net losses in Q2 2025 as it advances its lead MASH drug candidate, EFX, through a global Phase 3 clinical program.
Akero Therapeutics reports a net loss for Q1 2025 and discusses the progress of its Phase 3 SYNCHRONY program for efruxifermin (EFX).
Akero Therapeutics reports increased R&D spending in Q3 2024 as it advances its Phase 3 MASH program, while maintaining a strong cash position.
Akero Therapeutics, a clinical-stage biotech company, released its Q2 2024 financial results, highlighting increased R&D spending and ongoing clinical trial progress for its lead drug candidate, EFX.
Akero Therapeutics reports a net loss of $53.3 million for Q1 2024, alongside a significant increase in cash reserves following a successful follow-on public offering.